In this multicenter study, we evaluated the cumulative burden of morbidity (CBM) among . 1,200 testicular cancer survivors and applied factor analysis to determine the co-occurrence of adverse health outcomes (AHOs).
INTRODUCTION
The number of cancer survivors has increased markedly in recent decades, with an estimated 18 million in the United States by 2022.
1 Given these increasing numbers, having an understanding and quantifying the late effects of cancer and its treatment to inform survivorship care strategies are important. An important population in which to assess adverse health outcomes (AHOs) are survivors of testicular cancer, the most common cancer in men ages 18 to 39 years.
2 Since effective cisplatin-based chemotherapy was introduced in the 1970s, 3 the overall age-adjusted 5-year relative survival rate is . 95%, 4 and survivors remain at risk for decades for the late effects of cancer and its treatment. Characterization of AHOs is facilitated by the homogeneity of treatment regimens. For four decades, therapy for advanced testicular cancer typically has consisted of platinum-based chemotherapy. For good-risk disease, standard treatment comprises either three cycles of bleomycin, etoposide, and cisplatin (BEP 3 3) or four cycles of etoposide plus cisplatin (EP 3 4), whereas for intermediate-or poor-risk testicular cancer, four cycles of BEP (BEP 3 4) or four cycles of etoposide, ifosfamide, and cisplatin (VIP 3 4) are administered. 5, 6 Although treatment of good-risk testicular cancer with BEP 3 3 versus EP 3 4 results in lower cisplatin exposure, it is accompanied by potential bleomycin adverse effects. 7 To our knowledge, no study has evaluated the cumulative burden of morbidity (CBM) after BEP 3 4 versus VIP 3 4 or after BEP 3 3 versus EP 3 4 and has taken into account both the number and the severity of AHOs. Such characterization is important to develop risk-stratified, evidence-based follow-up recommendations. Moreover, as noted previously, 8 a better understanding of AHOs may help to guide testicular cancer management, especially in the controversial area of whether good-risk patients should receive EP 3 4 or BEP 3 3.
To provide new information about CBM after contemporary cisplatin-based chemotherapy for testicular cancer, we examined both the number and the severity of AHOs among 1,214 testicular cancer survivors enrolled in the Platinum Study, a large, multicenter clinical investigation. 9 We evaluated the co-aggregation of AHOs to identify co-occurring clusters and identified clinical, sociodemographic, and behavioral factors associated with an elevated CBM.
PATIENTS AND METHODS

Study Population
The Platinum Study was approved by each participating institution's institutional review board, and all participants provided written informed consent. The cohort was described in detail previously.
2,10 Briefly, eligible testicular cancer survivors had a histologic/serologic diagnosis of germ cell tumor, were age # 55 years at diagnosis, completed first-line cisplatinbased chemotherapy $ 1 year previously, and were undergoing routine follow-up at the participating site. All participants are referred to as testicular cancer survivors. At study enrollment, participants reported current prescription medication use with indication, underwent a brief physical examination, and completed comprehensive health questionnaires. Cancer diagnosis and treatment data were abstracted from medical records (Appendix, online only). Testicular cancer survivors indicated the average time per week of participating in various physical activities during the past year. 11, 12 These activities were grouped into vigorous ($ 6 metabolic equivalent tasks) and nonvigorous (, 6 metabolic equivalent tasks) activities (Appendix). 13 
Measurement of AHOs
Participant responses were mapped to individual AHOs and graded according to severity on a 0 to 4-point scale using a modified version of the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.03) 14 as in prior studies. 15, 16 A multidisciplinary panel of experts agreed on all grades (C.F., H.D.S., D.M.S., S.D.F., L.H.E., and L.B.T.). Appendix Table A1 (online only) lists individual AHOs and grading criteria. 15, 16 If no response was provided (, 1%), the AHO was conservatively treated as no symptom/diagnosis. CBM score was calculated on the basis of the number and severity of AHOs by following methods adapted from Geenen et al 15 (Appendix Table A2 , online only). A secondary CBM score, CBM Pt , was calculated using AHOs previously related to cisplatin exposure (ie, peripheral sensory neuropathy, autonomic neuropathy, hearing damage, tinnitus, kidney disease).
17,18
Statistical Analysis
Discrete and continuous data were described using numbers (percentages) and medians (ranges), respectively. Sociodemographic, health behavior, and treatment variables were individually tested for association with CBM score using t (continuous variables) or Pearson's x 2 (categorical variables) test. Variables then were combined in a multivariable ordinal logistic regression model, with CBM score as the dependent variable. Unless otherwise noted, variables with Wald x 2 P value $ .1 in the full model were removed from the final model. In the latter, the very high and severe CBM categories were collapsed given sparse data. Multivariable models that investigated the effect of cumulative cisplatin dose on CBM Pt score included the same covariates as the main model, except that chemotherapy regimen was omitted given its strong correlation with cumulative cisplatin dose.
Ordinal logistic regression examined the relationship between CBM score and self-reported health (the dependent variable). For all ordinal logistic regression models, the assumption of proportionality of odds across response categories was confirmed by comparing the Bayesian information criterion for the proportional odds model to that from a partial proportional odds model. Stata 14.1 software (StataCorp; College Station, TX) was used for all descriptive statistics and regression analyses.
Cluster analysis of variables was performed with nonlinear factor analysis and the nonparametric conditional item-pair covariance method of the cross-validated dimensionality evaluation to enumerate contributing traits procedure (Appendix). Each AHO was dichotomized: grades 0 and 1 were combined, and grades 2, 3, and 4 were combined. Because of sparse numbers, transient ischemic attack and stroke were collapsed into a single AHO; hypertriglyceridemia and hypercholesterolemia were combined into hyperlipidemia. Average item-pair odds ratios (ORs) were calculated by averaging the log OR across AHO pairs and then by exponentiating the average value.
RESULTS
Median age at evaluation for 1,214 testicular cancer survivors was 37 years (range, 18 to 74 years), and median time since chemotherapy completion was 4.2 years (range, 1 to 30 years; The most prevalent AHOs of any severity were obesity (41.7% grade 2, 26.0% grade 3, 3.9% grade 4), sensory neuropathy (28.3% grade 1, 14.5% grade 2, 13.4% grade 3), tinnitus (25.0% grade 1, 7.1% grade 2, 7.5% grade 3), and hearing damage (24.5% grade 1, 13.5% grade 2, 1.2% grade 3; Table 2 ). Raynaud phenomenon occurred in approximately 33% of participants (15.6% grade 1, 8.7% grade 2, 9.1% grade 3) and pain in approximately 25% (13.6% grade 1, 9.8% grade 2, 1.5% grade 3). Hypogonadism (10.2% grade 2) and erectile dysfunction (15.9% grade 1, 12.5% grade 2) also were observed. Of the 52 participants treated with VIP 3 4, 44% had mediastinal disease, whereas 47% had disease confined to the testis; in the remainder (9%), other extragonadal sites were involved. This contrasts with the smaller percentage of participants with mediastinal disease (ie, # 7.2%) in the other treatment groups. e Other chemotherapy regimens were cisplatin and ifosfamide (n = 25); cisplatin, vinblastine, and bleomycin (n = 6); ifosfamide, bleomycin, cisplatin, and etoposide (n = 6); and other cisplatin-based regimens (n = 32). 11, 12 that asks participants to report their average time per week (over the past year) spent at each of nine recreational activities: walking or hiking (including walking to work); jogging (. 10 min/mile); running (# 10 min/mile); bicycling (including stationary bike); aerobic exercise/dance or exercise machines; lower-intensity exercise, yoga, stretching, or toning; tennis, squash, or racquetball; lap swimming; and weight lifting or strength training. Each physical activity was assigned a MET value, which is a commonly used metric for describing the relative energy expenditure of a specific type of physical activity (1 MET = 1 kcal/kg/h or the energy cost of sitting quietly). The MET values for each activity were then used to calculate MET-h/wk for each participant, and these were grouped into categories of vigorous or nonvigorous physical activity according to standard definitions. Figure 1 Table A3 (online only). In a multivariable model ( Table 3 ) that controlled for time since chemotherapy and enrollment center, the following were significantly associated with higher CBM score: older attained age (OR, 1.18 per 5 years), BEP 3 4 (OR, 1.44 v BEP 3 3), VIP 3 4 (OR, 1.96 v BEP 3 3), less than a college-level education (OR, 1.44), current disability leave (OR, 3.53) , and former or current smoking status (OR, 1.28). Although the OR for VIP 3 4 was slightly higher than that for BEP 3 4, the difference was not significant (P = .36). Disease stage was not associated with CBM score (P = .48), which suggests that increased scores after BEP 3 4 or VIP 3 4 were not explained by more-advanced tumor status. CBM scores after EP 3 4 and BEP 3 3 were similar (P = .65). No significant differences were observed for individual AHOs except Raynaud phenomenon (P , .001), for which prevalence and severity after BEP Asian race (OR, 0.41) and vigorous exercise (OR, 0.68) were inversely associated with higher CBM score. Lower risk in Asian testicular cancer survivors reflects that fewer participants had higher severity grades for 15 of 22 AHOs versus white survivors (eg, peripheral sensory neuropathy: 8.5% v 13.5% grade 3; hearing loss: 8.5% v 14.1% grade 2, 0% v 1.2% grade 3). Similar trends were observed for autonomic neuropathy, tinnitus, Raynaud phenomenon, pain, kidney disease, hypertension, coronary artery disease, peripheral artery disease, obesity, thyroid disease, depression/anxiety, erectile dysfunction, and hypogonadism.
The relationship between cumulative cisplatin dose and overall CBM score was of borderline significance (OR per 100 mg/m 2 , ‡On the basis of patient-reported outcomes. §Among participants with grade 0, 1, 2, and 3 autonomic neuropathy, 22, seven, two, and one, respectively, reported that they take a b-blocker. kCalculated using weight and height assessments from the physical examination conducted at clinical evaluation.
¶Common Terminology Criteria for Adverse Events (version 4.03) does not include a grade 1 for obesity. #On the basis of prescription medication use. 1.16; 95% CI, 0.99 to 1.37; P = .064) in the multivariable model. However, when limited to conditions previously attributed to cisplatin, 14,15 each 100 mg/m 2 increase in cumulative dose was associated with significantly worse CBM Pt (OR per 100 mg/m 2 , 1.34; 95% CI, 1.14 to 1.58; P , .001).
CBM Score
Increasing CBM score was significantly associated with worse self-reported health. Compared with testicular cancer survivors with a score of 0, the risk of worse self-reported health among those scored as very low, low, medium, high, or very high/severe was 1.94 (95% CI, 1.08 to 3.48), 2.82 (95% CI, 1.72 to 4.62), 5.91 (95% CI, 3.56 to 9.81), 10.90 (95% CI, 6.28 to 18.93), and 34.17 (95% CI, 16.54 to 70.62), respectively.
Results from both variable clustering methods converged in the analysis of AHOs to yield six major groups of signs/symptoms (x 2 for model fit, P , .001), with pairwise ORs for given clusters as follows: hearing loss/damage, tinnitus (OR, 16.3); metabolic disorders (diabetes, hypertension, hyperlipidemia; OR, 9.8); neuropathy and related conditions (sensory neuropathy, autonomic neuropathy, pain, Raynaud phenomenon; OR, 5.5); cardiovascular disease (CVD) and related conditions (coronary artery disease, stroke, kidney disease, peripheral artery disease, thromboembolism, obesity; OR, 5.0); erectile dysfunction, thyroid disease (OR, 4.2); and hypogonadism, depression/anxiety (OR, 2.8). Clusters hearing loss/damage, tinnitus and neuropathy and related conditions, although distinct, were strongly correlated (r = 0.658; P , .001), as were clusters erectile dysfunction, thyroid disease and hypogonadism, depression/anxiety (r = 0.914; P , .001).
DISCUSSION
To our knowledge, the results are based on the largest study to date in testicular cancer survivors administered contemporary cisplatin-based chemotherapy. We characterize the CBM by showing that even at a young age, approximately one in five patients has a score of high to severe, with only 5% reporting no AHOs. Although CBM was higher in participants treated with BEP 3 4 or VIP 3 4 (v BEP 3 3), scores did not differ significantly between the two regimens (P = .36). CBM score also did not differ between BEP 3 3 and EP 3 4, the standard approaches for goodrisk disease. The higher prevalence and severity of Raynaud phenomenon after BEP 3 3 is consistent with the known relationship with bleomycin, 7 although Raynaud phenomenon also may be related to cisplatin. 19 Increasing cumulative cisplatin dose significantly increased risk for a higher CBM score for AHOs related to neuropathy, ototoxicity, and kidney disease. The strong association between higher CBM score and worse self-reported health indicates that the score reflects a health status perceptible to patients. These and other new findings are discussed next.
Previous US investigations of testicular cancer survivors 2, [20] [21] [22] [23] [24] have been limited in scope, generally by either not addressing AHOs 21,23,24 or evaluating fewer than five conditions 22 (Appendix Table A4 , online only). Although three studies obtained treatment information from medical records, only Oh et al 22 (143 patients) examined AHOs (n = 4) by therapy. Hashibe et al 20 evaluated AHOs through linkage with International Classification of Diseases, Ninth Revision, codes, but results were not presented by treatment, and only 168 patients received chemotherapy (type unspecified). In contrast, we evaluated a wide spectrum of AHOs by type and severity among . 1,200 testicular cancer survivors with detailed treatment information. The resultant CBM score comprises a range of AHOs likely related to testicular cancer and its treatment and to long-term platinum retention. After chemotherapy completion, circulating serum platinum remains measurable at levels up to 1,000 times above normal for 20 years.
25
Ongoing endothelial cell and vascular damage 26 occur for many years, and long-term serum platinum levels have been significantly related to neuropathy, 27 hypertension, 28 and hypercholesterolemia.
28 , and cisplatin. *Age at diagnosis was not included in the model given the strong correlation with age at evaluation (r = 0.81), which was included.
†See Table 1 footnote o and the Appendix for details on the assessment of physical activity.
‡Retroperitoneal lymph node dissection was retained in the multivariable model to control for potential residual confounding given its correlation with chemotherapy regimen (P , .001); approximately 34%, 55%, 66%, and 44% of testicular cancer survivors treated with BEP 3 3, EP 3 4, BEP 3 4, and VIP 3 4, respectively, had a retroperitoneal lymph node dissection.
§Disease stage was not significantly associated with cumulative burden of morbidity score (P = .48), which suggests that increased scores after BEP 3 4 or VIP 3 4 were not explained by a more-advanced tumor status.
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Because testicular cancer occurs largely in white males, 29 data on Asian patients are sparse. Decreased risks of a higher CBM score in Asian versus white testicular cancer survivors largely reflect the lower occurrence of high-severity grades in Asians for most AHOs. These include known treatment-related toxicities, which possibly reflects differences in drug absorption, distribution, metabolism, and excretion, among others. Although we adjusted for sociodemographic and health behavior factors, other unmeasured influences may have accounted for this finding, which remain to be confirmed.
Although the CBM score was slightly higher after VIP 3 4 than after BEP 3 4, the difference was not significant (P = .36). Both are standard chemotherapy regimens for intermediate-and poor-risk disease 5, 6 and show equivalent survival. Although an early, randomized trial showed that VIP 3 4 is associated with greater acute toxicity than BEP 3 4, 30 no study has subsequently addressed longterm AHOs as we have done. Additional follow-up, as planned for this cohort, is required to quantify further the CBM associated with each regimen. CBM also was similar for BEP 3 3 versus EP 3 4, the two commonly applied regimens for good-risk disease. In a curable disease such as testicular cancer with a long life expectancy and equivalent therapy options, the availability of AHO data becomes increasingly important to inform treatment decisions.
8
The striking association between CBM score and self-reported health indicates that the score captures outcomes that affect patients' self-perception of health. The risk of worse self-reported health among patients with very high/severe CBM scores rose to . 30-fold compared with those with a score of 0. These results also underscore the need to assess outcomes that affect self-perceived health because these can guide the development of survivorship care strategies that patients value.
To our knowledge, we have performed the first variable-based factor analysis of AHOs in long-term cancer survivors. Prior analyses have largely been conducted in patients either during cancer treatment, 31,32 shortly after therapy completion, 33, 34 or during palliative/hospice care. 35 Only Kim et al 36 evaluated patients who were either 2 to 5 years (n = 66) or . 5 years (n = 56) postcancer diagnosis, although some were still undergoing treatment. Factor analysis provides insights into groups of conditions that may co-occur and perhaps share etiology. For example, hearing loss and tinnitus reflect known cisplatin-associated damage to the auditory system. 10, 37 Associations between neuropathy and Raynaud phenomenon have been reported in individuals with no chemotherapy exposure, 38, 39 although the biologic basis is incompletely understood, and cooccurrence could reflect symptom cross-reporting. Pain is frequently associated with chemotherapy-induced peripheral neuropathy, with no agents currently available for prevention or treatment. 40 The cluster of hyperlipidemia, hypertension, and diabetes present at the time of clinical evaluation represents components of the metabolic syndrome, 41 consistent with studies that report increased metabolic syndrome risk among European testicular cancer survivors. [42] [43] [44] [45] The co-occurrence of AHOs related to CVD supports European investigations who showed a 1.4-fold to sevenfold higher CVD risk among cisplatin-treated testicular cancer survivors versus either the general population or patients managed with surgery alone. 26, [46] [47] [48] [49] Presentation with one or more of these AHOs suggests closer screening for other cluster-related conditions that could signal an elevated risk for CVD morbidity and mortality.
7 Hypogonadism and depression, respectively, represent a biologic consequence of testicular cancer treatment 50,51 and possibly associated psychological outcomes. A potential relationship between hypogonadism and depression in the general population has been recognized, with other symptoms including muscle weakness and loss of energy. [52] [53] [54] [55] [56] An association of erectile dysfunction and thyroid disease has not been previously shown in testicular cancer survivors as it has in noncancer populations. [57] [58] [59] [60] [61] [62] [63] Of 39 testicular cancer survivors with thyroid disease, 33 and six reported hypothyroidism and hyperthyroidism, respectively. Although associations of hypothyroidism 57, 62, 63 and hyperthyroidism 57,61-63 with erectile dysfunction were observed in several studies in noncancer populations, a relationship with hypothyroidism was not confirmed in the largest investigation to date, 61 possibly because of the low prevalence, and requires additional investigation.
The strong association between vigorous physical activity and lower CBM score as well as with a reduced absolute number of AHOs in prior analyses 2 can inform future intervention strategies. Studies of childhood cancer survivors have shown that exercise reduces the risk of late effects, such as CVD, 64 and the same likely applies to testicular cancer survivors. The apparent inverse relation between increased risk of a high CBM score and follow-up time is due to the disproportionate contribution of early-onset toxicities (eg, neuropathy, tinnitus), which are more prevalent than later-onset toxicities (eg, hypercholesterolemia, hypertension), which reflects the relatively short median follow-up time and young cohort age.
A major strength of this study is the estimation of both the number and the severity of AHOs in a large testicular cancer survivorship cohort treated primarily with EP 3 4, BEP 3 3, BEP 3 4, or VIP 3 4 chemotherapy regimens. Other strengths include the high participation rate (93%), detailed medical chart abstraction, and estimation of risk without the confounding effect of radiotherapy. An inherent limitation to all cross-sectional studies is the inability to assess causality between clinical, sociodemographic, and health behavior characteristics and CBM score. AHOs largely were self-reported without baseline data, similar to previous testicular cancer survivorship studies. 21, 23, 65 As in Geenen et al, 15 a limitation is that we could not compare the CBM score with that of a normative population given the unavailability of data. Equivalent weight was assigned to all AHOs, whereas testicular cancer survivorship may weigh these differently; some AHOs capture symptoms that can markedly affect survivors (eg, neuropathy), whereas others encompass conditions treated by medications that may be less bothersome (eg, hypertension). Additional studies are needed to investigate the effect of specific AHOs on health-related quality of life in this understudied population.
In conclusion, at a median follow-up of only 4.2 years, approximately one in five testicular cancer survivors have a CBM score of high, very high, or severe. Of note, no difference in CBM score was observed among survivors who received BEP 3 4 versus VIP 3 4 chemotherapy or among those given EP 3 4 versus BEP 3 3, although the long-term monitoring of patients is important. The value of variable clustering analysis in revealing the co-occurrence of AHOs is underscored by our findings and should be considered for other groups of long-term cancer survivors to highlight potential areas of research into the mechanistic bases of toxicities. Ongoing genetic research in the current cohort has already begun to characterize biologic pathways that underlie cisplatin-related toxicities 66, 67 and that can identify new research opportunities aimed at developing agents to prevent, mitigate, and treat adverse sequelae not only among testicular cancer survivors but also among other survivors after cisplatin-based chemotherapy. In the interim, if confirmed, the current results could inform survivorship care strategies and assist health care providers in identifying conditions, or groups of conditions, for which to screen, counsel, and treat testicular cancer survivors.
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Data Collection From Medical Records and Clinical Evaluation
Study personnel were trained in person to abstract data using a standard protocol and forms modified from previous investigations 11 [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] [192] 2002) . Detailed data on cancer diagnosis and treatment, including names and doses of all cytotoxic drugs were abstracted directly from medical records.
Sociodemographic Characteristics, Patient-Reported Health Outcomes, and Lifestyle Behaviors Patient-reported outcomes and lifestyle behaviors were assessed through self-reporting using validated questionnaires. 11, 12, [68] [69] [70] [71] To minimize recall bias, we applied strict definitions to assessment times. Validated questionnaires that queried symptoms over the past 4 weeks were selected, and for those adverse health outcomes (AHOs) for which Common Terminology Criteria for Adverse Events (version 4.03) grading took into account prescription medication use (ie, peripheral sensory neuropathy, pain, kidney disease, hypercholesterolemia, hypertriglyceridemia, hypertension, diabetes, peripheral artery disease, thromboembolic event, thyroid disease, anxiety/depression, erectile dysfunction, hypogonadism), we only took into account current prescription medication use (with usage for . 1 month), with data provided by the patient at the time of clinical assessment. For sociodemographic characteristics, we assessed current marital and employment status. Self-reported race and education level were determined at the time of enrollment. For health behaviors, we used standardized questions drawn from validated survey tools to assess current or former smoking status, alcohol consumption, and physical activity over the past year. For health behaviors, we used validated questionnaires to assess current or former smoking status, alcohol consumption, and physical activity over the past year. Exercise was assessed with a validated questionnaire 11,12 that asked participants to report their average time per week (over the past year) spent in each of nine recreational activities: walking or hiking (including walking to work); jogging (. 10 min/mile); running (# 10 min/mile); bicycling (including stationary bike); aerobic exercise/dance or exercise machines; lower-intensity exercise, yoga, stretching, or toning; tennis, squash, or racquetball; lap swimming; and weight lifting or strength training. Each physical activity was assigned a metabolic equivalent task (MET) value, which is a commonly used metric for describing the relative energy expenditure of a specific type of physical activity (1 MET = 1 kcal/kg/h or the energy cost of sitting quietly). 11 The MET values for each activity were then used to calculate MET-hours per week for each participant, and these were grouped into categories of vigorous or nonvigorous physical activity according to standard definitions (Ainsworth, et al: Med Sci Sports Exerc 43:1575 -1581 , 2011 ).
Measurement of AHOs
Symptoms related to a single underlying condition were grouped to avoid overcounting (eg, coronary artery disease was defined as a single AHO by combining coronary artery disease, angina, heart attack or myocardial infarction, and related procedures). For 12 AHOs in which current prescription medication use determined grade, medications were only considered if participants started use during or after cancer treatment.
Statistical Analysis
Nonlinear factor analysis used the probit link and WLSMV (weighted least squares means and variance) estimation with Mplus software (Muthén, et al: 2017) and the nonparametric conditional item-pair covariance method of the cross-validated dimensionality evaluation to enumerate contributing traits procedure (Monahan, et al: Appl Psychol Meas 31:483-503, 2007; Zhang, et al: Psychometrika 64:213-249, 1999 ) using the expl.detect function from the sirt (supplementary item response theory) R package (https://CRAN.R-project.org/package=sirt) and its default N.est option of a 50-50 split in training and validation data sets for replications. NOTE. For conditions that are based on more than one question, the severity grade was assigned according to the response that reported the greatest or most severe symptom. Abbreviations: AHO, adverse health outcome; BMI, body mass index; HDL, high-density lipoprotein; NA, not applicable (data needed to assign grade were not captured). *Assessed with the European Organisation for Research and Treatment of Cancer Chemotherapy-Induced Peripheral Neuropathy 20-item quality-of-life questionnaire on the basis of symptoms experienced over the past 4 weeks. 68 For each item, participants were asked whether the symptom started before, during, or after chemotherapy. If participants responded that the symptoms started before chemotherapy, those responses were not considered when assigning severity grade.
†Assessed with the Scale for Chemotherapy-Induced Long-Term Neurotoxicity questionnaire on the basis of symptoms experienced over the past 4 weeks. 69 For each item, participants were asked whether the symptom started before, during, or after chemotherapy. If participants responded that the symptom started before chemotherapy, those responses were not considered when assigning severity grade.
‡Prescription medications taken for at least the past 4 weeks were only used to assign grade if the participant reported that the indication was for the given AHO and that the medication was started during or after chemotherapy.
§Item is from the Hearing Handicap Inventory by Ventry and Weinstein 70 and assessed symptoms at the time of clinical evaluation. For each item, participants were asked to report the age (in years) at first occurrence. If onset of symptoms was before their age of germ cell tumor diagnosis, those responses were not considered when assigning severity grade. kItem is from the 36-Item Short Form Survey and assessed symptoms experienced over the past 4 weeks. 71 ¶BMI is based on physical examination performed at time of clinical assessment. 15 Modifications include division of the low category into very low and low and division of the high category into high and very high to reflect the granularity of data collected in the current study. k Other chemotherapy regimens not included in the comparisons are EP other than four cycles (n = 28), BEP other than three or four cycles (n = 28), VIP other than four cycles (n = 12), and other platinum-based regimens (n = 72). ii Refer to the Methods section and Appendix Table A1 in Fung et al   2 for definitions of adverse health outcomes, which also were stratified by type of chemotherapy. Adverse health outcomes are based on patient report. Diagnoses of hypertension, hypercholesterolemia, and diabetes required that patients have been told by a physician that they had the condition and that they currently were taking prescription medications for the condition. Percentages are shown for hypercholesterolemia. Hypertriglyceridemia also was assessed (incidence rate, 0.7 and 0.6/1,000 PY for the case and control groups, respectively; HR, 1.0; 95% CI, 0.37 to 2.70). The incidence rate of dyslipidemia (defined as high triglycerides, high cholesterol, and low high-density lipoprotein) was 9.7 and 8.7/1,000 PY for the case and control groups, respectively (HR, 1.14; 95% CI, 0.86 to 1.49). No definitions were provided for hypercholesterolemia, hypertriglyceridemia, or dyslipidemia.
